Copper-lowering agents as an adjuvant in chemotherapy

被引:15
作者
Kadu, Pramod [1 ]
Sawant, Bhakti [1 ]
Kale, Pravin Popatrao [2 ]
Prabhavalkar, Kedar [2 ]
机构
[1] SVKMS Dr Bhanuben Nanavati Coll Pharm, Dept Pharmaceut, Mumbai 400056, Maharashtra, India
[2] SVKMS Dr Bhanuben Nanavati Coll Pharm, Dept Pharmacol, Mumbai, Maharashtra, India
关键词
Adjuvant therapy; angiogenesis; chemotherapy; copper-chelating agents; copper in cancer cells; ANTICANCER DRUG CISPLATIN; CHELATING AGENT; D-PENICILLAMINE; HEPATOCELLULAR-CARCINOMA; CANCER-CELLS; TETRATHIOMOLYBDATE; TRIENTINE; ZINC; DISULFIRAM; TRIAL;
D O I
10.4103/ijp.IJP_68_20
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Copper is an important element essential for metabolism and normal human body function. Although it is an essential element, related imbalance leads to toxic effects. Studies have proved that there is an increase in copper level in cancer cells. Evidences suggest the link between increase in copper levels and progression of various types of cancers. Different strategies have been utilized to decrease the level of copper in various types of cancer cells. However, it was observed that cell machinery involved in copper homeostasis plays critical factor in lowering copper levels in cancer cells. The outcomes of many monotherapies consisting copper-lowering agents for the treatment of different types of cancers showed that the inhibition of single factor is not sufficient to inhibit the growth of cancer cells. The combination of copper-lowering agent with chemotherapeutic agent showed synergistic effect. Interestingly, the presence of copper-lowering agent in such combinations significantly improved the efficacy of chemotherapeutic agent. The present work has focused on the discussion of outcomes of studies involving anti-copper agent and chemotherapeutic agent and related future strategies.
引用
收藏
页码:221 / 225
页数:5
相关论文
共 35 条
  • [1] ANTICOPPER TREATMENT INHIBITS PSEUDOPODIAL PROTRUSION AND THE INVASIVE SPREAD OF 9L GLIOSARCOMA CELLS IN THE RAT-BRAIN
    BREM, S
    TSANACLIS, AMC
    ZAGZAG, D
    [J]. NEUROSURGERY, 1990, 26 (03) : 391 - 396
  • [2] The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease
    Brewer, George J.
    [J]. JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2014, 28 (04) : 372 - 378
  • [3] Copper-lowering therapy with tetrathiomolybdate for cancer and diseases of fibrosis and inflammation
    Brewer, GJ
    [J]. JOURNAL OF TRACE ELEMENTS IN EXPERIMENTAL MEDICINE, 2003, 16 (04) : 191 - 199
  • [4] Brewer GJ, 2000, CLIN CANCER RES, V6, P1
  • [5] In vitro search for synergy and antagonism:: evaluation of docetaxel combinations in breast cancer cell lines
    Budman, DR
    Calabro, A
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (01) : 41 - 46
  • [6] Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity
    Chen, Di
    Cui, Qiuzhi Cindy
    Yang, Huanjie
    Dou, Q. Ping
    [J]. CANCER RESEARCH, 2006, 66 (21) : 10425 - 10433
  • [7] Pathophysiology and clinical features of Wilson disease
    Ferenci, P
    [J]. METABOLIC BRAIN DISEASE, 2004, 19 (3-4) : 229 - 239
  • [8] Ferenci P, 2012, J HEPATOL, V56, P671, DOI 10.1016/j.jhep.2011.11.007
  • [9] Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies
    Fu, Siqing
    Hou, Ming-Mo
    Wheler, Jennifer
    Hong, David
    Naing, Aung
    Tsimberidou, Apostolia
    Janku, Filip
    Zinner, Ralph
    Piha-Paul, Sarina
    Falchook, Gerald
    Kuo, Macus Tien
    Kurzrock, Razelle
    [J]. INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 465 - 472
  • [10] A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer
    Gartner, Elaina M.
    Griffith, Kent A.
    Pan, Quintin
    Brewer, George J.
    Henja, Gwen F.
    Merajver, Sofia D.
    Zalupski, Mark M.
    [J]. INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 159 - 165